EUCTR2012-000870-51-ES进行中（未招募）不适用
RANDOMIZED CLINICAL TRIAL TO ASSESS THE EFFICACY OF TESTOSTERONE UNDECANOATE, METFORMIN, OR THE COMBINATION OF BOTH, FOR THE TREATMENT OF ISOLATED HYPOGONADOTROPIC HYPOGONADISM AND ERECTILE DYSFUNCTION IN OBESE MALES
nidad de Gestión Clínica de Endocrinología y Nutrición0 个研究点开始时间: 2012年9月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Men aged 18 to 65 years.
- •2. BMI ? 30 kg/m2.
- •3. Total testosterone levels <3.5 ng/dl.
- •4. LH levels <7.7 mIU / ml.
- •6. No evidence of any other pituitary hormone disruption in morning blood sample (normal concentrations of TSH, FT4, Prolactin, ACTH, cortisol and IGF-1
- •7. Being able to provide informed consent before randomization and agree to comply with all the procedures included in the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 72
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Intolerance/allergy to metformin or testosterone undecanoate.
- •2. Previous diagnosis of diabetes mellitus (HbA1c> 6.5% or fasting glucose> 126 mg/dl or glucose> 200 mg/dl after an oral glucose tolerance test)
- •3. Treatment with oral hypoglycemic agents, insulin or GLP-1 analogs.
- •4. Poor kidney function: serum creatinine> 2.0 mg / dl.
- •5. Previous history of prostate cancer or breast cancer.
- •6. Active cancer of any kind.
- •7. History of liver tumor or acute or chronic liver disease with impaired liver function: total bilirubin> 2.0 mg / dl or GOT levels three times the upper limit of normal.
- •8. Central hypogonadism of organic cause
- •9. Use in the past 12 months of any drug that affects the pituitary-gonadal axis.
- •10. Use of oral testosterone, oral or transdermal within 2 weeks prior to study entry, or any testosterone ester in the last 6 weeks or testosterone undecanoate injection in the 6 months prior to study entry.
- •11. Uncontrolled hypertension (SBP> 160 mmHg or DBP> 100 mmHg) despite adequate antihypertensive therapy.
- •12. HIV infection or known active infection with HBV or HCV.
- •13. Thrombotic or embolic disease.
- •14. Heart disease, kidney or liver disease.
- •15. Epilepsy or migraine not adequately controlled with treatment.
- •16. Hematocrit> 50% in the screening.
- •17. PSA> 4 ng / ml.
- •18. Severe benign prostatic hypertrophy with an IPSS scale score over 19.
- •19. Evidence of drug or alcohol abuse (> 50 g alcohol / day)
- •20. Hematological diseases that produce increased risk of bleeding after intramuscular injection.
- •21. Serious underlying disease that might affect the patient's ability to participate in the study (eg ongoing infection, gastric ulcers, active autoimmune disease).
- •22. Reduced life expectancy (<12 months) by the presence of comorbidities or advanced terminals.
- •23. Participation in another clinical trial within 30 days before study entry.
- •24. Previous diagnosis of hemochromatosis
研究者
相似试验
尚未招募
2 期
Randomized Clinical Trial To assess the effecacy of Aragwadhadi taila in comparison with betadine liquid in management of Dushta vranaCTRI/2022/07/044160DR AMRUTA ARVIND NARKAR
招募中
3 期
To asses the Efficacy, Safety and Tolerability of 4-month regimen containing Ofloxacin compared to theStandard 6-month regimen in the treatment of patients withSuperficial tuberculosis lymphnodeCTRI/2013/03/003481Indian Council of Medical Research
招募中
3 期
A clinical trial to study the effectiveness and safety of 3- and 4-month regimens as compared to the standard 6-month regimen for the treatment of infectious pulmonary tuberculosis patientsCTRI/2008/091/000024Indian Council of Medical Research1,650
尚未招募
2 期
Study held to see the effect of Acute fissure in Ano with Yashtimadhu tail comparison With Lignocaine 2% Ointment for Local Application.CTRI/2020/12/030028Dr Ajay kumar Anand
尚未招募
2 期
Study Of Use Of Pashanbhedadi Ghanvati In The Treatment Of Enlargement Of Prostate.CTRI/2020/11/029083Preeti Bhalke